Description:
Overview
Matrilin proteins can be utilized to inhibit catabolic enzyme production and cell hypertrophy in chondrocytes during Osteoarthritis.
Market Opportunity
Osteoarthritis (OA) hallmarks include chronic low-grade inflammation and cartilage cell (chondrocyte) enlargement (hypertrophy), which heavily contribute to cartilage erosion. Preventing these pathological phenomena in cartilage tissue is central to preventing OA progression. Matrilins are a family of extracellular matrix proteins that have been demonstrated to inhibit catabolic enzyme production and prevent cell hypertrophy in human cell culture and in animal models.
Innovation and Meaningful Advantages
We have successfully utilized an injectable recombinant version of a matrilin protein that can subside cartilage erosion in rabbits that were developing post-traumatic OA. We have established the ideal dose range to prevent OA in small animals using this approach.
Collaboration Opportunity
We are interested in exploring 1) startup opportunities with investors; 2) collaborations with leading medical research companies to conduct a large animal trial; and 4) licensing opportunities with companies.
Principal Investigator
Qian Chen Ph.D
Professor of Orthopaedic Research and Medical Science
Director, NIH Center of Biomedical Research Excellence in Skeletal Health and Repair
Vice Chairman for Research, Department of Orthopaedics
IP Information
US patent 10,130,687 Issued 11/20/2028